Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14801 - 14825 of 15502 in total
DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications. DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. EP3 is a target that associates with increased risk of various vascular...
Investigational
Matched Description: … DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor ... first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and
Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. As an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide....
Experimental
Investigational
Matched Description: … voltage- activated potassium channels, and nicotinic acetylcholine receptors. ... experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and ... still being investigated, but it is known that tetraethylammonium blocks autonomic ganglia, calcium- and
M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys. It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes. It will be of major benefit to those patients not responding satisfactorily...
Investigational
Matched Description: … It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce …
TRO40303 is under investigation in clinical trial NCT01374321 (Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction).
Investigational
Matched Description: … TRO40303 is under investigation in clinical trial NCT01374321 (Safety and Efficacy Study of TRO40303 …
2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-tnf Therapy).
Investigational
Matched Description: … 2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of …
Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent and
Investigational
Investigational
Experimental
4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency of fentanyl in analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted thiophenes and thiazoles are more potent still, as they are closer bioisosteres to the 4-carbomethoxy group of carfentanil.
Illicit
Matched Description: … analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted thiophenes and
Molidustat is under investigation in clinical trial NCT03350321 (A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects).
Investigational
Experimental
Displaying drugs 14801 - 14825 of 15502 in total